What is tucatinib/tucatinib?

Tucatinib/Tucatinib is a targeted drug whose mechanism of action is to prevent the growth and spread of cancer cells by interfering with the signal transduction of cancer cells. This class of drugs is often used as adjuvant therapy, especially for patients with advanced or metastatic cancer. Its indications mainly include the following two categories:

1. Metastatic breast cancer (MBC): For patients with advanced breast cancer, especially those with HER2-positive cases, the combination therapy of tucatinib with trastuzumab and capecitabine is widely used. This combination therapy is particularly suitable for patients with breast cancer that cannot be surgically removed or whose cancer has spread to other parts of the body, including brain metastases. These patients may have previously experienced one or more anti-HER2-based treatment regimens. Tucatinib can effectively inhibit the activity of HER2 receptors, thereby curbing the growth and spread of cancer cells.

2. Unresectable or metastatic colorectal cancer (CRC): For patients with RAS wild-type, HER2-positive colorectal cancer, when traditional drugs such as fluoropyrimidine-, oxaliplatin-, and irinotecan-based treatments are ineffective and the disease progresses, the combination therapy of tucatinib and trastuzumab has become an effective treatment option. This therapy helps control the progression of the disease by targeting the HER2 receptor to inhibit the proliferation of cancer cells.

In summary, tucatinib, as a new treatment for HER2-positive breast cancer, brings hope to patients with metastatic cancer who previously had poor response to other chemotherapy regimens. By combining tucatinib with other drugs, patients' survival can be effectively prolonged and their quality of life improved. However, during the use of the drug, patients need to pay close attention to possible adverse reactions and follow the doctor's guidance for treatment.